The litigation, spearheaded by the firm Levi & Korsinsky, centers on claims that Insulet misled shareholders regarding the severity of cannula tear issues at its Acton, Massachusetts facility. Following a March 2026 Medical Device Correction, management publicly characterized the defects as limited to specific, isolated batches, asserting that only 1.5% of annual production was affected. The complaint alleges these statements were designed to maintain artificially inflated share prices while failing to disclose that the quality-control failures were, in fact, process-wide.

Market confidence eroded when a second corrective disclosure on May 26, 2026, revealed the problem spanned multiple product lines—including Omnipod 5, Dash, and legacy Eros models—impacting approximately 7 million pods. The disclosure triggered a 5.07% drop in share price, compounding the 6.88% decline seen after the initial March announcement. According to the lawsuit, the company's internal reports, including 476 Medical Device Reports identified by the FDA, contradicted the limited scope initially presented to the public. Investors seeking to participate in the class action are advised to retain documentation of their purchase dates and losses, as the court-mandated deadline for lead plaintiff applications is August 31, 2026.